What is happening with not recommended drugs for dementia in Argentina? Prescription patterns and direct costs analysis
| العنوان: | What is happening with not recommended drugs for dementia in Argentina? Prescription patterns and direct costs analysis |
|---|---|
| المؤلفون: | Ricardo Mastai, Julián Bustin, Martín Cañás, Ignacio Demey, Diego Sarasola, Fabián Triskier, Santiago O'Neill, Martín Urtasun, Galeno Rojas |
| المصدر: | International Journal of Geriatric Psychiatry. 35:270-275 |
| بيانات النشر: | Wiley, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | medicine.medical_specialty, Happening, Argentina, 03 medical and health sciences, Pharmacoeconomics, Indirect costs, 0302 clinical medicine, Pharmacotherapy, Piperidines, Alzheimer Disease, medicine, Humans, Dementia, Medical prescription, Psychiatry, Cognitive impairment, Retrospective Studies, 030214 geriatrics, business.industry, Pharmacoepidemiology, medicine.disease, Psychiatry and Mental health, Indans, Cholinesterase Inhibitors, Geriatrics and Gerontology, business |
| الوصف: | The only recommended pharmacological treatments for specific dementias are donepezil, galantamine, rivastigmine, and memantine (recommended drugs, RD). However, other drugs without recommendations (not recommended drugs, NRD) are often used to treat patients with cognitive impairment (CI) in Argentina. The INSSJyP is the largest health insurance in Argentina. The objective of this study is to analyze the prescription pattern, cost, and implications of NRD used for the treatment of CI in the INSSJyP.This is a retrospective, population-based study of the INSSJyP outpatients' prescriptions database for drugs usually prescribed for CI during 2015. These data were compared with the same database in 2009. The number of "prescriptions" always refers to dispensed packages.A total of 3 255 438 packages of drugs usually indicated for CI were prescribed during 2015: 1 912 476 packages of RD (59%) and 1 342 962 packages of NRD (41%).Comparing the results with those obtained in 2009, there is a 148% gross increase in the prescription of both RD and NRD for CI, although the rates/1000 affiliates/year show a lesser rise for NRD (70.1%) compared to RD (103.9 %).The expenditure on CI drugs prescribed during 2015 was 77 million USD. NRD cost represented approximately 20 million USD.Inappropriate drug use increases health costs in developing countries. We found a high number of patients with a probable diagnosis of CI treated with NRD. It is extremely relevant that all the healthcare professionals can update their knowledge and modify behavioral insights about appropriate prescription for specific dementias. |
| تدمد: | 1099-1166 0885-6230 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c30d79d76c794074fce8134b8629b7a2 https://doi.org/10.1002/gps.5242 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....c30d79d76c794074fce8134b8629b7a2 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10991166 08856230 |
|---|